Skip to main content
Genotype-dependent efficacy of a Dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas
Published Web Location
http://europepmc.org/articles/PMC3360787?pdf=renderNo data is associated with this publication.
Abstract
The PI3K (phosphatidylinositol-3-kinase)/mTOR (mammalian target of rapamycin) pathway is frequently activated in endometrial cancer through various PI3K/AKT-activating genetic alterations. We examined the antitumor effect of NVP-BEZ235-a dual PI3K/mTOR inh
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.